Nanoscale Particles for Lung Delivery of siRNA
Journal of Drug Delivery Science and Technology, ISSN: 1773-2247, Vol: 22, Issue: 1, Page: 99-108
2012
- 10Citations
- 15Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Abstract Description
Small interfering RNAs (siRNAs) are potent molecules capable of blocking gene expression after entering cell cytoplasm. Despite their strong efficacy, they need to be carried by nanoscale delivery systems that can protect them against degradation in biological fluids, increase their cellular uptake and favor their subcellular distribution. Several studies have highlighted the potential of local pulmonary delivery of siRNAs for the treatment of lung diseases. For this purpose, nanoscale delivery systems were addressed to target passively or actively the target cell. This review discusses the possibilities of approaching lung delivery of nanoscale particles carrying siRNAs.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S1773224712500109; http://dx.doi.org/10.1016/s1773-2247(12)50010-9; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84857405522&origin=inward; http://linkinghub.elsevier.com/retrieve/pii/S1773224712500109; http://api.elsevier.com/content/article/PII:S1773224712500109?httpAccept=text/xml; http://api.elsevier.com/content/article/PII:S1773224712500109?httpAccept=text/plain; https://linkinghub.elsevier.com/retrieve/pii/S1773224712500109; http://dx.doi.org/10.1016/s1773-2247%2812%2950010-9; https://dx.doi.org/10.1016/s1773-2247%2812%2950010-9
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know